National Osteoporosis Society (UK) appeals against NICE treatment appraisal

1258
The National Osteoporosis Society (UK) is calling upon its 25,000 members to join in a campaign to appeal the NICE final appraisal determination (FAD) on treatment.

The National Osteoporosis Society in the UK (NOS) is calling upon its 25,000 members to join in a campaign to appeal the NICE final appraisal determination (FAD) on treatment. NOS fears that as a result of the NICE treatment appraisal hundreds of thousands of people with osteoporosis may be left without mandatory viable treatment options.

The final appraisal determination on treatments for the primary and secondary prevention of osteoporosis represents a significant improvement on NICE's earlier draft appraisal. Nevertheless, the NOS has serious concerns about the lack of provision for second line treatments - drugs that can be prescribed for patients if they cannot take or fail to respond to alendronate. Alendronate is unsuitable for up to 1 in 4 patients, so without mandatory alternative treatments, significant numbers of patients may receive no treatment for osteoporosis through the NHS and consequently risk breaking bones unnecessarily.

"While we welcome the significant step forward that this new appraisal represents, we have decided that the NOS should formally appeal against NICE's decision," explains Claire Severgnini, NOS chief executive. "This appraisal needs to look beyond first line treatment: NICE must recognise the needs of the hundreds of thousands of osteoporosis patients for whom alendronate will not be a viable treatment. NICE should support a range of cost effective treatment options in order to protect all patients from fractures according to their individual needs - a ‘one treatment for all' policy is unfair and short-sighted."

To read the complete NOS press release – and to download the petition (for UK residents), visit the [link http://www.nos.org.uk/]NOS website[/link]

Region: